Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Study of Systemic Therapy With Immunotherapy Combined With Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) in Unresectable Locally Advanced Gastric Cancer

NCT07607119 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT07607119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07607119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Study of Systemic Therapy With Immunotherapy Combined With Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) in Unresectable Locally Advanced Gastric Cancer
Lead sponsor
Samsung Medical Center
Phase
Not applicable
Overall status
Recruiting
Start date
May 15, 2026
Completion date
April 30, 2030
Enrollment
53 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, locally advanced gastric cancer, stomach neoplasms, unresectable gastric cancer